Drug Profile
ACT 001
Alternative Names: ACT-001Latest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Accendatech
- Class Antineoplastics; Lactones; Sesquiterpenes; Small molecules
- Mechanism of Action NF-kappa B inhibitors; STAT3 transcription factor inhibitors; Thyroid hormone binding protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Brain metastases; Interstitial lung diseases
- Phase I/II Glioblastoma
- No development reported Solid tumours
Most Recent Events
- 09 Sep 2023 Interim efficacy and adverse events data from a phase II trial for Interstitial lung diseases and Idiopathic pulmonary fibrosis presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Glioblastoma(In children, Late-stage disease, Second-line therapy or greater) in Australia (PO)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in China (PO)